Experts are increasingly focused on retatrutide, a novel treatment created by Eli Lilly, as a potential advance in weight management. Distinct from many earlier approaches, retatrutide is a twin-action agonist targeting simultaneously GLP-1 and GIP, substances that impact satiety and blood glucose